Sen. Baucus Urges More Comparative Research At Vioxx Hearing
Executive Summary
The Vioxx withdrawal demonstrates the need for more comparative research on drugs, Sen. Max Baucus (D-N.M.) suggested in his questioning of witnesses at the Senate Finance Committee's hearing on Merck's withdrawal of the COX-2 inhibitor
You may also be interested in...
Senate Drug Pricing Hearing Looms As Unparalleled Event For Pharma
From Vioxx to EpiPen, industry has been called in to testify before Congress on a range of issues. But with seven big pharma leaders having accepted the Senate Finance Committee's invitation Feb. 26, the stage is set for some exceptional political theater.
Senate Drug Pricing Hearing Looms As Unparalleled Event For Pharma
From Vioxx to EpiPen, industry has been called in to testify before Congress on a range of issues. But with seven big pharma leaders having accepted the Senate Finance Committee's invitation Feb. 26, the stage is set for some exceptional political theater.
Vioxx Hearing May Be Sign Of Things To Come Under Medicare Rx
The Senate Finance Committee should continue to review FDA's drug safety procedures in light of the upcoming expansion of the Medicare program, Ranking Democrat Max Baucus (D-Mont.) maintained during the committee's Nov. 18 hearing on Vioxx